Genetic and microbial regulation of NOD2 signaling in homeostasis and disease
en-GBde-DEes-ESfr-FR

Genetic and microbial regulation of NOD2 signaling in homeostasis and disease

18/11/2026 HEP Journals

Intracellular sensing of bacteria is a narrow business, and NOD2 performs one specialised part of it. The receptor recognises muramyl dipeptide, a conserved fragment of peptidoglycan released when bacteria remodel their cell walls, and it responds by activating NF-κB and MAP kinase signalling, producing cytokines and antimicrobial peptides. Positioned in the cytoplasm rather than on the surface, it detects organisms that have breached the epithelium or that are being degraded inside phagocytes, which makes it a second line of defence and a calibrator of the first. Its expression is concentrated in Paneth cells of the small intestine, in monocytes and in intestinal epithelial cells, and that distribution already hints at where its dysfunction will show first.
Clinical genetics attached the gene to disease in a way few discoveries match. Loss-of-function variants, particularly the frameshift mutation near the leucine-rich repeat region, confer the strongest known single-gene risk for Crohn's disease, an effect large enough to reshape the mechanistic questions of an entire field. The early interpretation was straightforward: reduced bacterial sensing weakens barrier defence, bacteria translocate, inflammation follows. Later evidence complicated that chain, because NOD2 also regulates autophagy, antigen presentation, Paneth cell function and the composition of the microbial community itself, so one variant can act through several routes at once. The consequence is that NOD2 sits at a junction rather than at the end of a linear pathway, and that the phenotype of a risk allele depends on what else is present in the gut.
Microbial regulation is the newer half of the story, and it inverts the usual direction of causation. NOD2 requires ligand, and ligand supply depends on which bacteria are present. Species that lack the DL-endopeptidase enzymes needed to release muramyl dipeptide from peptidoglycan fail to stimulate the receptor, so a microbiota deficient in those organisms produces functional NOD2 silencing even in a person carrying two intact copies of the gene. Dysbiosis of this kind has been documented in inflammatory bowel disease and in other conditions, which extends the receptor's significance well beyond Crohn's disease and reframes it as a sensor whose sensitivity is set by ecology rather than by inheritance alone. The reframing also changes what a therapeutic would have to do: restoring ligand supply is a different intervention from correcting a gene. Animal models colonised with defined bacterial communities made that dependence testable in ways human association studies could not, by holding genotype constant while varying the organisms present.
Two translational implications follow, and both are practical. Nutritional rehabilitation in childhood undernutrition illustrates the first. Linear growth failure that persists beyond the age of two is often irreversible, and microbiota disruption limits the effectiveness of therapeutic feeding. Oral supplementation with a strain of Lactiplantibacillus plantarum promoted growth in undernourished juvenile mice with a conventional microbiota, even while they received a protein- and fat-deficient diet, and the effect ran through muramyl dipeptide production and NOD2 activation in intestinal epithelial cells; the same taxon has been identified as growth-associated in cohorts of undernourished children in Bangladesh. Therapeutic modulation of the axis is therefore plausible, whether through defined probiotics, ligand supplementation or dietary strategies that favour ligand-producing organisms. The second implication concerns how such interventions should be tested. Genetic inactivation and microbial inactivation may not be equivalent, since downstream signalling, effector cell types, cytokine profiles and the spectrum of associated diseases may differ, and longitudinal cohorts stratified by genotype and microbiota, together with CRISPR-edited organoids, are the tools that would separate them. Distinguishing the two matters because a probiotic can restore ligand supply in one case and do nothing in the other, and only stratified evidence will show which patients fall into which group. What remains untested is whether ligand restoration changes outcomes in patients whose receptor is intact but under-stimulated.
DOI
10.1007/s11684-026-1239-6
Attached files
  • Fig1 Timeline of key discoveries in NOD2 research.
18/11/2026 HEP Journals
Regions: Asia, China, Bangladesh, North America, United States
Keywords: Science, Life Sciences

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by AlphaGalileo Terms Of Use Privacy Statement